Mainz Biomed Appoints Dr. Soren Thestrup-Nielsen M.D. to Strategic Advisory Board
November 18 2021 - 3:01AM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, announced today the appointment of Dr. Soren
Thestrup-Nielsen M.D. to its Strategic Advisory Board.
“It’s a pleasure to welcome Soren to our newly formed Strategic
Advisory Board as he brings us tremendous leadership in all aspects
of a product’s life cycle,” commented Guido Baechler, Chief
Executive Officer of Mainz Biomed. “All of us at the company are
excited to work with Soren as we embark on ColoAlert’s commercial
roll-out across Europe and develop the regulatory and clinical
strategy for the U.S. market.”
Dr. Thestrup-Nielsen has spent over 25 years in the medical
device industry, first at Boston Scientific and later at Danaher
Corporation where he led the inorganic growth of Danaher’s acute
care and laboratory diagnostics portfolio. He has previously held a
series of notable executive roles including Chairman of Althea
Group, as well as board member at numerous companies including lung
cancer screening company Oncimmune. During his career Dr.
Thestrup-Nielsen has overseen IPO’s, trade-sales, acquisitions, and
a variety of investment transactions with medical companies in both
North America and Europe. He received a M.D. from the University of
Copenhagen, School of Medicine, practiced 5 years as a general
& vascular surgeon, and received an MBA from the IMD in
Lausanne, Switzerland.
In his advisory role with Mainz Biomed, Dr. Thestrup-Nielsen
will take an active role in the development of the Company product
strategy for Europe, the United States, and the rest of the world,
to include clinical development, market segmentation, go-to-market
strategy, and regulatory strategy. He will also provide expert
counsel on the development of the global commercial strategy, the
development of the clinical strategy for future iterations of Mainz
Biomed’s ColoAlert test and lead the clinical advisors board once
established.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic
solutions for life-threatening conditions. The Company's flagship
product is ColoAlert, an accurate, non-invasive, and easy-to-use
early detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed across Europe. In the USA, Mainz Biomed will
begin the clinical study and regulatory process in the first half
of 2022 for U.S. FDA approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information please visit
www.mainzbiomed.com
For media enquiries, please contact
press@mainzbiomed.com
For investor enquiries, please contact
ir@mainzbiomed.com
Forward Looking Statements
Certain statements made
in this press release are “forward-looking statements” within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be
identified by the use of words such as “anticipate”, “believe”,
“expect”, “estimate”, “plan”, “outlook”, and “project” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
forward-looking statements reflect the current analysis of existing
information and are subject to various risks and uncertainties. As
a result, caution must be exercised in relying on forward-looking
statements. Due to known and unknown risks, actual results may
differ materially from the Company’s expectations or projections.
The following factors, among others, could cause actual results to
differ materially from those described in these forward-looking
statements: (i) the failure to meet projected development and
related targets; (ii) changes in applicable laws or regulations;
(iii) the effect of the COVID-19 pandemic on the Company and its
current or intended markets; and (iv) other risks and uncertainties
described herein, as well as those risks and uncertainties
discussed from time to time in other reports and other public
filings with the Securities and Exchange Commission (the “SEC”) by
the Company. Additional information concerning these and other
factors that may impact the Company’s expectations and projections
can be found in its initial filings with the SEC, including its
Prospectus filed on October 12, 2021 and amended on October 25,
2021 and November 1, 2021. The Company’s SEC filings are available
publicly on the SEC's website at www.sec.gov. Any forward-looking
statement made by us in this press release is based only on
information currently available to Mainz Biomed and speaks only as
of the date on which it is made. Mainz Biomed undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024